Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa

Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa

Zenocutuzumab is a humanized bispecific IgG1 antibody targeting HER2 and HER3 to enhance antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth. It is being developed for the treatment of cancers overexpressing HER2 and HER3, leveraging dual targeting for enhanced antitumor activity. M. W 145.88 kDa

Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa

Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa

Emicizumab is a recombinant, humanized, bispecific antibody that binds Factor IXa and Factor X to mimic Factor VIII function. It is used to treat hemophilia A. M.W 146.82 kDa

Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa

Tebotelimab is a humanized bispecific DART molecule targeting PD-1 and LAG-3, with immunomodulatory and antineoplastic activities. It enhances T-cell activation by blocking both checkpoints and has shown anti-tumor activity, including in combination with anti-HER2 therapies. M.W 165.68 kDa

Zanidatamab is a humanized bispecific IgG1 monoclonal antibody targeting two non-overlapping epitopes of HER2 (ECD2 and ECD4), with immunomodulating and antineoplastic activities. It has shown anti-tumor activity across various solid tumors with HER2 expression or amplification. M.W 148.28 kDa

Emb-02 is a bispecific antibody targeting the immune checkpoints PD-1 and LAG-3, with potential antitumor effects. It restores effector T cell function and enhances antitumor activity. M. W 146.82 kDa